Clinical and Economic Impact of Glatiramer Acetate Versus Beta Interferon Therapy Among Patients With Multiple Sclerosis in a Managed Care Population

Abstract

Glatiramer acetate is associated with reductions in the incidence of relapse and costs of care relative to the beta interferons among this large group of managed care patients with MS.